Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
VelosBio initiates Phase 2 trial for ROR1-targeting antibody-drug conjugate VLS-101 in solid tumors
VelosBio, a San Diego-based biopharmaceutical company, has reached a significant milestone in the development of its investigational antibody-drug conjugate (ADC), VLS-101. The company announced that ... Read More
Alliqua BioMedical to acquire Adynxx, forming new clinical-stage pharmaceutical leader
Pennsylvania-based Alliqua BioMedical has announced a significant merger with San Francisco's Adynxx, aiming to establish a clinical-stage pharmaceutical entity dedicated to non-opioid pain management therapies. ... Read More